Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals company Zydus Lifesciences announced Q2FY24 & H1FY24 results: Q2FY24: Revenue from operations at Rs 43,688 million, up 9% over last year. Research & Development (R&D;) investments for Q2FY24 stood at Rs 3,225 million (7.4% of revenues). EBITDA for Q2FY24 was Rs 11,461 million, up 41% YoY. EBITDA margin for Q2FY24 stood at 26.2%, an improvement of 580 bps on a YoY basis. Net Profit for Q2FY24 was Rs 8,007 million, up 53% YoY. Capex (organic) for Q2FY24 was Rs 2,162 million. H1FY24: Revenue from operations at Rs 95,084 million, up 19% over last year. Research & Development (R&D;) investments stood at Rs 6,464 million (6.8% of revenues). EBITDA was Rs 26,514 million, up 61% YoY. EBITDA margin stood at 27.9%, an improvement of 720 bps over the previous year. Net Profit was Rs 18,876 million, up 81% YoY. Capex (organic) for H1FY24 was Rs 4,365 million. "Our Q2 FY24 result represents stable growth in our key businesses, as well as strong profitability. We are on track to meet our growth objectives for the year. Going ahead, differentiated launches in the US, in addition to a rebound in India business growth which was constrained by delayed seasonality, will be critical drivers. We anticipate sustained momentum in profitability and aim for EBITDA margins of more than 24% in the current fiscal year.", said, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences. Result PDF08-11-2023